Evidence map›Paper›PMID 27027505›Full record

ArticlePloS one2016

CD4 Counts at Entry to HIV Care in Mexico for Patients under the "Universal Antiretroviral Treatment Program for the Uninsured Population," 2007-2014.

Alfonso C Hernández-Romieu, Carlos del Rio, Juan Eugenio Hernández-Ávila, Hugo Lopez-Gatell, José Antonio Izazola-Licea, Patricia Uribe Zúñiga, Mauricio Hernández-Ávila

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alfonso C Hernández-RomieuDepartment of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, United States of America.
Carlos del RioDepartment of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, United States of America.
Juan Eugenio Hernández-ÁvilaNational Institute of Public Health (INSP), Cuernavaca, Mexico.
Hugo Lopez-GatellNational Institute of Public Health (INSP), Cuernavaca, Mexico.
José Antonio Izazola-LiceaNational Center for Prevention and Control of HIV/AIDS (CENSIDA), Mexico City, Mexico.
Patricia Uribe ZúñigaJoint United Nations Programme on HIV/AIDS (UNAIDS), Evaluation and Economics Division, Geneva, Switzerland.
Mauricio Hernández-ÁvilaNational Institute of Public Health (INSP), Cuernavaca, Mexico.

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
EMORY AIDS INTERNATIONAL TRAINING AND RESEARCH PROGRAMD43TW001042 · FIC · EMORY UNIVERSITY · PI DEL RIO, CARLOS · 1998 to 2013
$6.8M
FIC NIH HHS D43 TW001042FIC NIH HHS D43 TW01042NIAID NIH HHS P30 AI050409
6 · The paper itself

Abstract

In Mexico, public health services have provided universal access to antiretroviral therapy (ART) since 2004. For individuals receiving HIV care in public healthcare facilities, the data are limited regarding CD4 T-lymphocyte counts (CD4e) at the time of entry into care. Relevant population-based estimates of CD4e are needed to inform strategies to maximize the impact of Mexico's national ART program, and may be applicable to other countries implementing universal HIV treatment programs. For this study, we retrospectively analyzed the CD4e of persons living with HIV and receiving care at state public health facilities from 2007 to 2014, comparing CD4e by demographic characteristics and the marginalization index of the state where treatment was provided, and assessing trends in CD4e over time. Our sample included 66,947 individuals who entered into HIV care between 2007 and 2014, of whom 79% were male. During the study period, the male-to-female ratio increased from 3.0 to 4.3, reflecting the country's HIV epidemic; the median age at entry decreased from 34 years to 32 years. Overall, 48.6% of individuals entered care with a CD4≤200 cells/μl, ranging from 42.2% in states with a very low marginalization index to 52.8% in states with a high marginalization index, and from 38.9% among individuals aged 18-29 to 56.5% among those older than 50. The adjusted geometric mean (95% confidence interval) CD4e increased among males from 135 (131,142) cells/μl in 2007 to 148 (143,155) cells/μl in 2014 (p-value<0.0001); no change was observed among women, with a geometric mean of 178 (171,186) and 171 (165,183) in 2007 and 2014, respectively. There have been important gains in access to HIV care and treatment; however, late entry into care remains an important barrier in achieving optimal outcomes of ART in Mexico. The geographic, socioeconomic, and demographic differences observed reflect important inequities in timely access to HIV prevention, care, and treatment services, and highlight the need to develop contextual and culturally appropriate prevention and HIV testing strategies and linkage programs.

Indexed as

AdolescentAdultAnti-HIV AgentsCD4 Lymphocyte CountFemaleHIV InfectionsHumansMaleMedically UninsuredMexicoMiddle AgedNational Health ProgramsSex DistributionYoung AdultAnti-HIV Agents

Identifiers

PMID27027505
PMCPMC4814060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.